Guides to Israel's cannabis market

Who can prescribe, how the Health Ministry and HMO routes differ, what it costs and how long approval takes — Israel's 2026 licence process explained.

Is weed legal in Israel for tourists? No. Foreign prescriptions have no legal standing, there is no tourist licence, and possession is only decriminalised.

Anxiety and depression are not approved indications in Israel, and the Health Ministry lists severe anxiety as a reason to refuse a permit. Here is why.

How cancer patients in Israel get a medical cannabis licence: who qualifies, which specialist prescribes, what Israeli evidence shows and what it costs.

Israel licenses cannabis for children with autism, epilepsy, Tourette syndrome and cancer. National data shows most families stop within six months.

Chronic pain is Israel's largest medical cannabis indication. How access works, what pain specialists think, and what the outcome data shows.

Israelis over 60 are a large share of medical cannabis patients. Here is what Israel's geriatric studies found about pain, function, side effects and stopping.

How medical cannabis is used for PTSD in Israel — how many patients, full Ministry of Defense funding for combat-related cases, and why the May 2026 plan to narrow who qualifies was frozen three days after it was published.

Renewal in Israel isn't automatic. Since April 2024 most patients renew via an HMO prescription, not an IMCU licence. How it works and how to avoid a gap.

A breakdown of what medical cannabis really costs in Israel — consultation, licence and pharmacy product — why prices vary, and who is funded.

Israeli regulators want medical cannabis patients off smoking and onto oils and metered-dose inhalers. What each format is, and how they differ.

Which conditions can qualify for a cannabis licence in Israel — the approved indications across oncology, pain, neurology and mental health.

Israel's Health Ministry lists 423 pharmacies licensed to sell medical cannabis. Where they are, which chains dominate, what to bring, and why prices differ.

Israel treats any trace of cannabis in a driver as an offence, and a medical licence is no defence. What the law says, how police test, what it costs.

Decriminalised does not mean legal. The 2019 reform, the 2022 regulations that replaced it, the fines that apply now, and what is still criminal.

CBD is not a dangerous drug in Israel below 0.3% THC. What that exemption actually covers, why food and cosmetics were left out, and what it means for visitors.

A Health Ministry committee proposed phasing out smoked cannabis — then the minister froze it. What the 2026 plan says, and where patients stand.

Where recreational cannabis legalization stands in Israel in 2026 — the failed bills, the politics blocking reform, and what is moving in the Knesset.

Is weed legal in Israel in 2026? Medical cannabis is legal by prescription, recreational is not, small-amount possession is decriminalised, CBD is exempt.

What Israel actually does about cannabis possession in 2026 — the fixed fines set by the 2022 regulations, where personal use ends, and when it turns criminal.

Israel's quality rules for medical cannabis, explained: how the IMC standards cover growing, manufacturing, distribution and the Medical Grade stamp.

A timeline of Israel's medical cannabis programme — from the first approvals in 1992 through per-product pricing and the 2024 HMO reform.

Israel's largest medical cannabis plant filed for insolvency with NIS 153m of debt. What the court filings say broke, and what creditors settled for.

A profile of IM Cannabis — the Nasdaq-listed operator's H1 2026 results, its going-concern warning, and the related-party sale of its European business to its own CEO.

Canndoc and its parent InterCure, Israel's largest licensed cannabis producer: business model, 2025 results, war-damage settlement and 2026 reverse split.

A factual overview of the publicly listed Israeli cannabis companies, how to access them, and the sector-specific risks — not investment advice.

Israel's cannabis export story has quietly changed: its biggest operators now earn serious money in Germany. What that revenue actually represents, who holds EU-GMP, and why Israel is still a net importer.

Cantek, Univo, BOL Pharma, Pharmocann, Bazelet, Tikun Olam: which Israeli cannabis companies went insolvent or were sold since 2022, for how much, and who bought them.

Panaxia was the first listed Israeli cannabis company with EU-GMP certification. It left the Israeli market, its listed shell became Barak Investment House, and it now operates from Malta.

Israel publishes no ranking of cannabis producers, but licence status, batch certificates, withdrawals and financial health are all public. How to check each one.

Tikun Olam pioneered Israeli medical cannabis and bred Avidekel. The company behind the brand now has no farms and no factory. How that happened.

How many licensed cannabis growers Israel actually has, who they are, how cultivation licences work, and why the domestic grower base is shrinking under Canadian import competition.

How Bedrocan and the Dutch Office of Medicinal Cannabis made cannabis a standardised pharmaceutical raw material — and set the template Israel followed.

The universities, centres and clinical programmes behind Israel's lead in cannabis research — from the Hebrew University's MCCR to the Technion.

How Israeli chemist Raphael Mechoulam isolated THC, discovered the body's own cannabinoids, and made Israel the founding home of modern cannabis science.

A plain-English guide to the endocannabinoid system — the body's own cannabinoid network, much of it discovered through Israeli research.

The 'entourage effect' — the Israeli-coined idea that cannabis compounds work better together than in isolation — and what the evidence actually shows.

Israel's medical cannabis patient numbers — a decade of growth, the first-ever decline after the HMO reform, the recovery to a record high, and what's driving the trend.

Where Israel's medical cannabis actually comes from — domestic cultivation versus imports, Canada's dominant role, the 2026 anti-dumping investigation, and why supply is so exposed to trade policy.

How Israel's cannabis market compares to Germany, Canada and the US — small in volume, outsized in research influence, and a net importer in a competitive global trade.

What Israel's medical cannabis market is actually worth — why published estimates disagree, a bottom-up volume check, the legal-versus-illicit gap, and what caps the market's size.